<DOC>
	<DOC>NCT02946216</DOC>
	<brief_summary>The study aims to explore the prevalence of ALK/ROS1/MET mutations assessed with ctDNA samples in EGFR-wildtype NSCLC</brief_summary>
	<brief_title>ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Histologically confirmed stage IIIB/IV NSCLC; Histologically confirmed adenocarcinoma; EGFRwildtype NSCLC; Provision of blood (plasma) sample for ctDNA testing; Patient must be able to comply with the protocol; Provision of blood (plasma) sample for ctDNA testing; As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease); Histologically confirmed small cell lung cancer or other metastatic tumors; Patient with no histologic or cytological diagnosis;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>